BioNTech Financials
| 0A3M Stock | USD 119.15 0.66 0.56% |
BioNTech |
Understanding current and past BioNTech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BioNTech's financial statements are interrelated, with each one affecting the others. For example, an increase in BioNTech's assets may result in an increase in income on the income statement.
BioNTech Stock Summary
BioNTech competes with Auction Technology, Ameriprise Financial, National Bank, Take Two, and Cognizant Technology. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. It employs 2500 people.| Instrument | UK Stock View All |
| Exchange | London IL |
| Business Address | An der Goldgrube |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.biontech.de |
| Phone | 49 6131 9084 0 |
| Currency | USD - US Dollar |
You should never invest in BioNTech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of BioNTech Stock, because this is throwing your money away. Analyzing the key information contained in BioNTech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
BioNTech Key Financial Ratios
There are many critical financial ratios that BioNTech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that BioNTech SE reports annually and quarterly.| Return On Equity | 0.24 | |||
| Return On Asset | 0.17 | |||
| Target Price | 219.54 | |||
| Beta | 0.24 |
BioNTech Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioNTech's current stock value. Our valuation model uses many indicators to compare BioNTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioNTech competition to find correlations between indicators driving BioNTech's intrinsic value. More Info.BioNTech SE is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.71 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for BioNTech SE is roughly 1.41 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNTech's earnings, one of the primary drivers of an investment's value.BioNTech SE Systematic Risk
BioNTech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BioNTech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on BioNTech SE correlated with the market. If Beta is less than 0 BioNTech generally moves in the opposite direction as compared to the market. If BioNTech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioNTech SE is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioNTech is generally in the same direction as the market. If Beta > 1 BioNTech moves generally in the same direction as, but more than the movement of the benchmark.
BioNTech November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BioNTech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BioNTech SE. We use our internally-developed statistical techniques to arrive at the intrinsic value of BioNTech SE based on widely used predictive technical indicators. In general, we focus on analyzing BioNTech Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BioNTech's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.15 | |||
| Information Ratio | 0.1005 | |||
| Maximum Drawdown | 30.16 | |||
| Value At Risk | (4.48) | |||
| Potential Upside | 5.71 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.